Update to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV

The Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV (Pediatric Opportunistic Infection Guidelines) have been updated.  

Major revisions within the last 6 months are as follows: 

COVID-19 

• Published a new section describing the approach to the prevention and management of COVID-19 in children with and exposed to HIV. 
• Added recommendations for the use of pre-exposure prophylaxis, including COVID-19 vaccination in all children and the monoclonal antibody pemivibart in certain populations. 
• Added recommendations for the treatment of COVID-19 with ritonavir-boosted nirmatrelvir, remdesivir, and/or corticosteroids, depending on the age of the child, clinical presentation, and risk factors for progression. 

All updates are developed by the subject matter groups listed in Appendix B of the guidelines and reviewed by editors and relevant outside reviewers before finalization. 

For a list of recent updates, please see What's New in the Guidelines. To view or download the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV, go to the Clinicalinfo website. The guidelines tables and recommendations also can be downloaded as separate PDF files. 

Clinicalinfo welcomes your feedback on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV. Please send your comments with the subject line “Pediatric Opportunistic Infections Guidelines” to HIVinfo@NIH.gov by July 24, 2024.